The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | HRQoL trajectories of patients with aggressive B-cell lymphomas treated with CAR T-cell therapy
Fabio Efficace, PhD, Italian Group for Adult Hematologic Diseases (GIMEMA), Rome, Italy, discusses the results of a prospective observational study examining the health-related quality of life (HRQoL) trajectories of patients with aggressive B-cell lymphomas treated with CAR T-cell therapy. He highlights significant impairments in HRQoL during the first month post-infusion, followed by substantial improvements observed up to 12 months in key health domains, such as pain and fatigue. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We presented a study around 170 patients treated in real life with CAR T-cell therapy because there is very little information about quality of life or patients treated with CAR-T in real life. So what we have seen is that during the first month, post-infusion, there are major impairments in terms of quality of life, in terms of fatigue, daily activities, and a number of toxicities as reported by patients themselves...
We presented a study around 170 patients treated in real life with CAR T-cell therapy because there is very little information about quality of life or patients treated with CAR-T in real life. So what we have seen is that during the first month, post-infusion, there are major impairments in terms of quality of life, in terms of fatigue, daily activities, and a number of toxicities as reported by patients themselves. Afterwards, what we have seen is that from six months up to 12 months, there are a substantial increase with regard to a number of domains, with regard to pain, fatigue, physical functioning. So the reassuring message for the patient is that from six months, they can see improvement, really clinical, I would say, relevant improvement. And another aspect that we have seen in this study is that cognitive functioning is not a major issue. We might have expected, for example, that due to the neurotoxicity of this drug, there could have been some kind of cognitive impairment from the patient perspective, but we haven’t seen any impact on these important aspects. So again, this is a reassuring message for the patient receiving this type of, let’s say, relatively novel approach.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
